Agoracom Blog Home

Posts Tagged ‘#smallcapstocks’

« Older Entries
Newer Entries »

Tetra Bio-Pharma $TBP.ca Takes One Step Closer to the Commercialization of Cannabis Oil-Based Retail Products $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:00 AM on Monday, September 24th, 2018

Logo tetrabiopharma rgb web

  • Made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health products market
  • Tetra and its clinical research partner, Santé Cannabis, announced that the clinical trial in non-cancer chronic pain patients will be completed later this autumn as promised

ORLEANS, Ontario, Sept. 24, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health products market.

Tetra and its clinical research partner, Santé Cannabis, announced that the clinical trial in non-cancer chronic pain patients will be completed later this autumn as promised.  This was the first clinical trial of its kind in evaluating the safety and efficacy of different doses and ratios of cannabis oils versus placebo.  The study included a dose titration phase (gradually bringing patients to the required dose) allowing us to better understand the side effect profile of the oils as well as the development of tolerance to these effects.  Thus far, no other company in the medical cannabis space has undertaken such an exhaustive study to understand the therapeutic benefits and side effects of a cannabis oil-based capsule.

Dr. Chamberland, interim CEO and CSO added, “We continue to deliver on our business model that provides for evidence-based research to support the usage of cannabis-derived products and provide the medical community with the data they have been demanding from this sector. The trial has already provided unique valuable clinical data on both safe and efficacious dose levels of CBD and THC-CBD oils.  This data will allow Tetra to advance to the next phase of product development wherein the company is developing products for its commercial partner Genacol Corporation Canada, as well as food supplements for the retail market and finally, our capsules that we intend to use in the treatment of chronic and cancer related pain.  Tetra has already established itself as a trailblazer in the natural health product segment with the announcement of our intention to launch a Hemp Energy Drink and we intend to build on that momentum.”

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of PPP005, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

 

Tags: , , , , , ,
Posted in Featured, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Takes One Step Closer to the Commercialization of Cannabis Oil-Based Retail Products $AERO $CBDS $CGRW $APH.ca $GBLX

INTERVIEW: American Creek #AMK.ca Discusses Potential Quantity and Grade of Gold Mineralization (1.8 – 1.9 Million Ounces @ 1.12 – 1.35 G/t) at the Treaty Creek $SEA $SA $SKE.ca $TUD.ca $PVG $MRO.ca

Posted by AGORACOM-JC at 8:36 AM on Monday, September 24th, 2018

Tags: , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, American Creek Resources Ltd. | Comments Off on INTERVIEW: American Creek #AMK.ca Discusses Potential Quantity and Grade of Gold Mineralization (1.8 – 1.9 Million Ounces @ 1.12 – 1.35 G/t) at the Treaty Creek $SEA $SA $SKE.ca $TUD.ca $PVG $MRO.ca

INTERVIEW: CFN Interviews Ryan Brown about $NBUD.ca Strategy $TLRY

Posted by AGORACOM-JC at 3:04 PM on Friday, September 21st, 2018

North Bud Farms Inc (C.NBUD) CEO Ryan Brown met with CannabisFN Media to lay out and explain the company’s strategic and future direction as the industry moves closer into Legalization 2.0.

The company is focusing on a sustainable production and procurement of cannabinoids while pursuing a license under the Access To Cannabis for Medical Purpose Regulations (ACMPR).

Tags: , ,
Posted in All Recent Posts, North Bud Farms Inc | Comments Off on INTERVIEW: CFN Interviews Ryan Brown about $NBUD.ca Strategy $TLRY

AGORACOM Welcomes North Bud Farms Inc. $NBUD.ca Focusing On Sustainable Low Cost, High Quality Cannabinoid Production

Posted by AGORACOM-JC at 8:43 AM on Friday, September 21st, 2018

Northbud large

WHY NORTH BUD FARMS INC?

  • Canadian regulatory door for CIP (Cannabinoid Infused Products) is opening in 2019
    As shown in other legal jurisdictions (Colorado, Washington, Nevada, California)
  • Infused products sector has become the highest margin segment of the industry
  • Positioned to be a raw input producer for this space
  • Currently working with multiple food, beverage and science companies to provide safe standardized cannabinoid infused raw inputs for large scale GMP manufacturing of products

THE OPPORTUNITY

  • Acquired late stage ACMPR applicant GrowPros
    MMP from Tetra Bio-Pharma (TSXV: TBP)
  • GrowPros MMP application was submitted in November 2014 and is currently in the ‘Confirmation of Readiness’ stage.
  • Phase 1 is located on 95 acres of agricultural farmland in Low, Québec.
  • Option exists to acquire more land if needed
  • Facility will focus on GMP (higher production grade) pharma-grade cultivation and food-grade extracted inputs

LOCATION

SITE DETAILS: LOW COST INFRASTRUCTURE

POSITIONED FOR LEGALIZATION 2.0

  • First mover advantage often becomes first-mover disadvantage
    Examples: AOL, Netscape, Yahoo, BlackBerry
  • Second mover advantage: clearer picture of market and competition
    Examples: Google, Facebook, Amazon, Apple, NORTHBUD

STRATEGIC VERTICALS

Pharma Development

  • North Bud will focus on GMP standardized production to be used by our pharma commercialization partners i.e. Tetra Bio-Pharma We will focus on securing unique strains containing high amounts of specific cannabinoids not typically found in recreational cannabis.

Food Grade Inputs

    • Using our licensed encapsulation technology we will
      engage existing food and beverage companies looking
      to develop product lines containing cannabis.

Tags: , , , , ,
Posted in AGORACOM Clients (New), All Recent Posts, North Bud Farms Inc | Comments Off on AGORACOM Welcomes North Bud Farms Inc. $NBUD.ca Focusing On Sustainable Low Cost, High Quality Cannabinoid Production

ReadyUp raises $2 million to manage #Esports teams and help players improve $GMBL $ATVI $TTWO $GAME $EPY.ca $TCEHF $Game.ca $EPY.ca

Posted by AGORACOM-JC at 1:29 PM on Thursday, September 20th, 2018
Dean Takahashi@deantak September 20, 2018 5:30 AM
  • ReadyUp, a platform for player connection and team management for gaming and esports, has raised $2 million in funding from game-savvy investors.
  • The combined company has 11 people in San Francisco, and they will focus on a few different missions related to esports, said Alemania, in an interview with GamesBeat.
Every business leader needs to truly understand how AI is a gamechanger. Join other senior execs at VB Summit, Oct 22 & 23, 2018 in Mill Valley, CA. Grab your ticket now at 30% off.

ReadyUp, a platform for player connection and team management for gaming and esports, has raised $2 million in funding from game-savvy investors.

Last month, ReadyUp acquired Ready Up Live, a gaming community site that was doing some of the same things as ReadyUp. That deal brought together a number of game veterans and celebrities, including Roderick Alemania, CEO of ReadyUp, and famous pro gamer and ReadyUp cofounder Johnathan “Fatal1ty” Wendel, and Ready Up Live founder Dan “Greenskull” Hammill, a celebrity gamer who has 262,000 subscribers on YouTube.

The combined company has 11 people in San Francisco, and they will focus on a few different missions related to esports, said Alemania, in an interview with GamesBeat.

“Our mission is to be the epicenter of the esports community, so that people can find people they actually want to play with,” he said. “The idea across the pillars of that mission is to meet, compete, and get better. And we have a really strong team of people who have been in the game business for decades.”

In terms of meeting, the company wants to create a matchmaking service where esports players can find people they want to play with, rather than just play pickup multiplayer games all of the time with strangers.

In terms of “compete,” the company will also help esports players find teams, and help teams find esports players, or even help players find others so they can form esports teams. Alemania compared this to the application TeamSnap, which helps parents deal with changes and details for their children’s sports team. In the case of players, this solution would help teams figure out who is playing in a particular match or is not available. This will enable team managers to focus on team and player development, rather than logistics.

And in terms of “get better,” ReadyUp will create a marketplace for services that parties can offer, such as coaching services for Fortnite. And it will provide other services that enable players to get better and play with their friends.

“We called our friends at the major publishers and asked if they were doing this, and they all said no,” Alemania said. “We saw we could fill a need in the market. It can address a massive pain point for teams.”

The cofounders like Wendell and Hammill get asked to provide coaching, paid or not, all of the time. But this marketplace would provide an organized way to scale up such services to a much larger level, Alemania said.

San Francisco-based ReadyUp was founded in 2017 to benefit amateur and professional gamers, teams, and gaming clans. The platform is set to launch later this year, with other services coming next year. Investors include Boost VC, which led the round, as well as Fenwick & West, Smith & Crown, and other individual investors from across gaming, sports, esports, blockchain and other sectors.

“ReadyUp will change competitive video gaming and esports on a fundamental level,” said Jay Cohen, former president of Wargaming America, in a statement. “By providing an on-ramp for gamer connection, player development, and competition, ReadyUp lets every gamer, team, and the esports industry as a whole to reach their full potential. The ReadyUp platform will not only accelerate the path to revenue for players, teams, and partners, it is the spark for the wildfire that is waiting to happen.”

Lead investor Boost VC is a blockchain and virtual reality accelerator with a portfolio of more than 200 companies including Coinbase.

“ReadyUp has assembled an awesome team of accomplished, experienced and well connected executives.” said Adam Draper, founder and managing partner, in a statement. “Their process of product validation and design coupled with a feedback loop from gamers puts ReadyUp in a great position to build a successful company that will capitalize on the $900 million esports industry.”

Source: https://venturebeat.com/2018/09/20/readyup-esports-team-management-firm-raises-2-million/

Tags: , , , ,
Posted in All Recent Posts, Esports Entertainment Group, Esports Entertainment Group Inc., eSports Investing | Comments Off on ReadyUp raises $2 million to manage #Esports teams and help players improve $GMBL $ATVI $TTWO $GAME $EPY.ca $TCEHF $Game.ca $EPY.ca

North Bud Farms $NBUD.ca Closes $944,500 Private Placement $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:40 AM on Thursday, September 20th, 2018

Northbud large

  • Announced the closing of a non-brokered private placement offering consisting of 3,778,000 units, at a price of $0.25 per Unit, for gross proceeds of $944,500.
  • Each Unit is comprised of one Common Share and one-half (1/2) of a Common Share purchase warrant, with each whole warrant entitling the holder hereof to acquire one additional Common Share at a price of $0.40 per Common Share until September 20, 2020

TORONTO, Sept. 20, 2018 – North Bud Farms Inc. (CSE: NBUD) (the “Corporation“), is pleased to announce the closing of a non-brokered private placement offering (the “Private Placement“) consisting of 3,778,000 units (“Units“), at a price of $0.25 per Unit, for gross proceeds of $944,500. Each Unit is comprised of one Common Share and one-half (1/2) of a Common Share purchase warrant, with each whole warrant entitling the holder hereof to acquire one additional Common Share at a price of $0.40 per Common Share until September 20, 2020.  No fees or commissions were paid in connection with the Private Placement.  The terms of the Private Placement are the same as the Corporation’s previously-completed private placement (July 25, 2018, as disclosed in the Corporation’s prospectus dated August 21, 2018).

Mr. Andre Audet, the Chairman of the Corporation, participated in the Private Placement by subscribing for 200,000 Units (the “Insider’s Participation“).  The Insider’s Participation is exempt from the formal valuation and minority shareholder approval requirements provided under Multilateral Instrument 61-101 Protection of Minority Holders in Special Transactions (“MI 61-101“) in accordance with sections 5.5(a) and 5.7(a) of MI 61-101. The exemption is based on the fact that neither the fair market value of the Insider’s Participation nor the consideration paid by such insider exceeds 25% of the Corporation’s market capitalization. The Corporation did not file a material change report at least 21 days prior to the completion of the Private Placement since the Insider’s Participation was not determined at that moment.

The Corporation intends to use the proceeds of the Private Placement to continue to advance the license application of GrowPros MMP Inc. under the Access to Cannabis for Medical Purposes Regulations (ACMPR) and for general working capital purposes.

The securities acquired by the subscribers are subject to a hold period of four months plus one day from the closing date, ending on January 21, 2019, except as permitted by applicable securities legislation.

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired from Tetra Bio-Pharma Inc. (TSX-V: TBP) (OTCQB: TBPMF) in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).   North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farm’s final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Tags: , ,
Posted in North Bud Farms Inc | Comments Off on North Bud Farms $NBUD.ca Closes $944,500 Private Placement $AERO $CBDS $CGRW $APH.ca $GBLX

Tetra Bio-Pharma $TBP.ca Announces Significant Progress on Storz & Bickel Co-Development in Treating #Fibromyalgia $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:09 AM on Thursday, September 20th, 2018

Logo tetrabiopharma rgb web

  • Made significant progress in its co-development partnership with Storz & Bickel
  • The study protocol has received approval from the Independent Ethics Board (IRB Services) and was recently submitted for review to Health Canada

ORLEANS, Ontario, Sept. 20, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has made significant progress in its co-development partnership with Storz & Bickel.  The study protocol has received approval from the Independent Ethics Board (IRB Services) and was recently submitted for review to Health Canada.  In addition, Tetra Bio-Pharma expects to complete the identification of every compound in the PPP001 vapor generated by the Mighty Medic vaporizer later this month.  Tetra intends on initiating a Phase 1 clinical study in healthy volunteers to determine the safety and pharmacokinetics of its vaporized PPP001 drug later this year.

This clinical data and vapor compound identification will allow Tetra to bridge to its existing and future clinical data of the Phase 3.  The bridge will provide a significantly reduced time to market and reduced development cost for the commercialization of PPP001 as a treatment for fibromyalgia.

“The Independent Ethics Board approval represents a major step forward prior to obtaining approval from Health Canada and the clinical study will allow Tetra to accelerate bringing PPP001 for fibromyalgia patients,” stated Dr. Guy Chamberland, Ph.D., Interim CEO and CSO at Tetra Bio-Pharma.  “We are very confident in Tetra’s strategy to become a global leader in the development of cannabinoid derived prescription and natural health products.”

About Storz & Bickel
STORZ & BICKEL built the first factory in the world for the manufacture of medical herbal vaporizers in Tuttlingen, Germany, a town with almost 500 medical device manufacturers. Tuttlingen is reputed to be the center of medical technology, where the first factory to produce surgical instruments was established more than 150 years ago.

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the approval of PPP001, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine
514-288-8500 ext. 226
[email protected]

Stephanie Engel
416-425-9143 ext. 209
[email protected]

Tags: , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Announces Significant Progress on Storz & Bickel Co-Development in Treating #Fibromyalgia $AERO $CBDS $CGRW $APH.ca $GBLX

CLIENT FEATURE: Star Navigation $SNA.ca Real-Time Flight Tracking and Monitoring Technology

Posted by AGORACOM-JC at 3:25 PM on Wednesday, September 19th, 2018

STAR-A.D.S.®

  • On-board real-time monitoring and data analysis system that provides a “virtual window into an aircraft”
  • As cost-effective air to ground communication system that automatically and securely transmits flight data and incident alerts.
  • Continuously monitors selected avionics systems on the aircraft from power-on to power-off, instantly analyzes the data, and transmits selected data and any incident alerts, via satellite to the operator.
  • Acts as an early warning system, detecting the earliest signs of potential problems
  • Performs these functions in “real-time” providing essential safety monitoring to the benefit of passengers, aircraft personnel, and ground crew
  • Applications include: Commercial Airlines, Helicopters, Business Aircraft, Assist Search and Rescue by providing last transmitted location
  • Recent applications: Emergency Medical Services (airborne and ground vehicles), Land vehicles

CHECK OUT RECENT INTERVIEW

FULL DISCLOSURE: Star Navigation Systems Group Ltd. is an advertising client of AGORA Internet Relations Corp.

Tags: , , , ,
Posted in AGORACOM Client Feature, Star Navigation Systems (SNA:TSXV) | Comments Off on CLIENT FEATURE: Star Navigation $SNA.ca Real-Time Flight Tracking and Monitoring Technology

#Esports: #Mastercard $MA comes on board as global sponsor for League of Legends #LOL in multi-year deal $GMBL $ATVI $TTWO $GAME $EPY.ca $TCEHF $Game.ca $EPY.ca

Posted by AGORACOM-JC at 11:30 AM on Wednesday, September 19th, 2018

  • Mastercard announced a multi-year global sponsorship deal with the popular League of Legends eSports title on Wednesday (Sept 19),
  • The company’s first such tie-up with an eSports partner
  • League of Legends is one of the world’s most widely played and followed eSports games, with about 100 million unique monthly users and its most-watched match pulling in over 80 million live unique viewers

Lester Wong

SINGAPORE – Mastercard announced a multi-year global sponsorship deal with the popular League of Legends eSports title on Wednesday (Sept 19), the company’s first such tie-up with an eSports partner.

League of Legends is one of the world’s most widely played and followed eSports games, with about 100 million unique monthly users and its most-watched match pulling in over 80 million live unique viewers.

Mastercard is also League of Legends parent company Riot Games’ first global sponsor. There are about 380 million eSports fans worldwide, according to market researcher Newzoo.

The deal will see Mastercard work with Riot to offer live-event activations and fan experiences across three major annual League of Legends tournaments: the Mid-Season Invitational, the All-Star Event, and the World Championship.

“eSports is a phenomenon that continues to grow in popularity, with fans that can rival those at any major sporting event in their enthusiasm and energy,” said Raja Rajamannar, Mastercard’s chief marketing and communications officer.

“This deal made a lot of sense for us. We’re a global brand and League of Legends is a global phenomenon so the scale is there. In-game purchases are a big part of eSports, and we are a payment solutions company.”

Rajamannar declined to reveal the exact value of the deal but said it was “very comparable” to Mastercard’s other global sponsorships in music and traditional sport with partners like the Grammy Awards and golf’s British Open, one of the sport’s four Major tournaments.

“We’re thrilled to team up with Mastercard on this ground-breaking partnership that will provide meaningful and long-term value to our fans,” said Naz Aletaha, head of eSports partnerships at Riot Games. “Mastercard is among the first of world-class brands to take such a big step into eSports at the global level, and we’re proud to have them support League of Legends eSports events alongside their other premier sports and entertainment sponsorships.”

Fan engagement efforts are set to kick off immediately in the South Korean, Chinese and Taiwanese markets ahead of the 2018 League of Legends World Championships in Seoul next month.

The first experiences available on Mastercard’s Priceless platform include the opportunity to watch a game at the championships with a pro player from VIP seats and behind-the-scenes tours of rehearsals.

Mastercard is also planning to launch a co-branded League of Legends credit card early next year.

Said Rajamannar: “We took two years to fully understand this space because we wanted to be clear how the consumers think. And what we found out is that they want brands to be authentic, organic and creative. So this collaboration is not just about how many cards we must sell but a long-term effort to engage consumers.”

Source: https://www.straitstimes.com/sport/esports-mastercard-comes-on-board-as-global-sponsor-for-league-of-legends-in-multi-year-deal

Tags: , , , , ,
Posted in All Recent Posts, Esports Entertainment Group, Esports Entertainment Group Inc., eSports Investing | Comments Off on #Esports: #Mastercard $MA comes on board as global sponsor for League of Legends #LOL in multi-year deal $GMBL $ATVI $TTWO $GAME $EPY.ca $TCEHF $Game.ca $EPY.ca

North Bud $NBUD.ca Farms to Begin Trading on the Canadian Securities Exchange

Posted by AGORACOM-JC at 8:17 AM on Wednesday, September 19th, 2018

Northbud large

  • will commence trading on the Canadian Securities Exchange at the opening of the market on Thursday, September 20, 2018 under the stock symbol NBUD

TORONTO, Sept. 19, 2018 — North Bud Farms Inc. (“NORTHBUD” or the “Company“) is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (“CSE”) at the opening of the market on Thursday, September 20, 2018 under the stock symbol “NBUD”.

“We are proud to achieve this milestone in advance of the historic legalization of Cannabis in Canada on October 17, 2018 and less than 10 months since the Company’s inception which is a testament to the dedication and execution of our experienced management team,” said Ryan Brown, Founder and CEO of North Bud Farms.

Concurrently with the CSE listing, the Company also announces that the board of directors has authorized the grant of 5,100,000 incentive stock options to certain of its directors, officers, employees and consultants. Each such option entitles the holder to acquire one common share for a period of 5 years at an exercise price of $0.25 per common share.

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired from Tetra Bio-Pharma Inc. (TSX-V: TBP) (OTCQB: TBPMF) in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).   North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Tags: , , , , ,
Posted in Featured, North Bud Farms Inc | Comments Off on North Bud $NBUD.ca Farms to Begin Trading on the Canadian Securities Exchange

« Older Entries
Newer Entries »